Haddadin Yezan Munther

Haddadin Yezan Munther is listed in filings as Director at Outlook Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 3, 2026, including purchase activity. Recent filings connect the profile to Outlook Therapeutics, Inc. (OTLK). The current snapshot covers public activity from Oct 3, 2024 to Jun 3, 2026. Reported amounts are shown as $24.1K to $101.7K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.